Cardiovascular Risk Assessment Tools in Type 2 Diabetes Mellitus: A Comparative Study from Nigeria

Oluwarotimi Olopade; Edna-Lorrine Ubezuo; Epkenyong Ekpenyong; Obiamaka Ede; Emmanuel Inya; Ifedayo Odeniyi; Olufemi Fasanmade

doi:10.1530/endoabs.117.P115

P115

Prev Next

Section Contents Cite

Endocrine Abstracts (2026) 117 P115 | DOI: 10.1530/endoabs.117.P115

SFEBES2026 Poster Presentations Metabolism, Obesity and Diabetes (68 abstracts)

Cardiovascular Risk Assessment Tools in Type 2 Diabetes Mellitus: A Comparative Study from Nigeria

Oluwarotimi Olopade ¹ , Edna-Lorrine Ubezuo ¹ , Epkenyong Ekpenyong ¹ , Obiamaka Ede ¹ , Emmanuel Inya ¹ , Ifedayo Odeniyi ^2,1 & Olufemi Fasanmade ^2,1

Author affiliations

¹Lagos University Teaching Hospital, Lagos, Nigeria; ²University of Lagos, Lagos, Nigeria

Background and Objectives: Cardiovascular disease is the leading cause of mortality in Type 2 Diabetes Mellitus (T2DM). Most risk calculators (Framingham, ASCVD, QRISK3) were developed in non-African populations, raising concerns about applicability. We compared these tools in Nigerian T2DM patients to identify the most suitable for local use.

Methods: A cross-sectional study of 223 T2DM patients at LUTH. Data were collected through clinical assessments and review of patient records. Cardiovascular risk was estimated using the Framingham, ASCVD, and QRISK3 risk scores. The agreement was tested with correlation coefficients and Bland-Altman plots

Results: A total of 223 participants were included in the study, with a mean age of 62.80 ± 9.5 years. Male: Female ratio is 1:1.4. 40.4% of the participants had a duration of DM < 5years. Framingham risk score (FRS) classified 55.1% of the participants as high risk (median 21.6%), QRISK3 classified 47.5% as moderate and 35.0% as low risk (median 12.1%), while ASCVD identified 39.5% as high risk (median 15.0%). QRISK3 correlated strongly with ASCVD (r = 0.88). Bland-Altman showed FRS consistently overestimated risk compared to both QRISK3 (+7.3%) and ASCVD (+1.67%).

Conclusion: Framingham risk score overestimates cardiovascular risk in Nigerian T2DM patients, while QRISK3 and ASCVD show closer agreement. QRISK3 may be a more suitable tool for risk stratification in this population, but prospective validation is needed.